Targeting Mitosis to Reprogram the Tumor Microenvironment: Combination Strategies for Cancer Immunotherapy
Year: 2026
Type: article
Abstract: Dysregulated mitosis is a therapeutic vulnerability in cancer, but the consequences of mitotic targeting extend beyond tumor-cell death. Chromosome missegregation, micronucleus formation, and chromatin-bridge exposure can activate cytosolic DNA sensing and alter inflammatory signaling, immune recognition, and stromal interactions within the tumor microenvironment (TME). These responses are not uniformly antitumor. Acute mitotic perturbation may enhance innate immune activation and tumor-cell susceptibility to immune elimination, whereas persistent chromosomal instability can promote inflammatory adaptation, myeloid immunosuppression, and immune escape. This distinction has important implications for combining antimitotic agents with immunotherapy. Here, we examine the molecular mechanisms linking mitotic disruption to TME remodeling, with particular emphasis on signaling through cyclic GMP–AMP synthase (cGAS) and stimulator of interferon genes (STING), immune checkpoint regulation, myeloid-cell responses, and stromal reorganization. We evaluate combination strategies involving immune checkpoint blockade, innate immune modulation, myeloid targeting, radiotherapy, and cell-death-enhancing interventions. Although preclinical studies provide mechanistic support for several approaches, clinical evidence remains uneven, and the immune consequences of individual antimitotic agents are difficult to predict across tumor types. We propose a testable framework integrating baseline chromosomal instability, p53 status, innate immune competence, and early treatment-induced biomarkers to guide therapeutic selection and scheduling. Translating this framework into clinical practice will require prospective validation, clearer separation of drug-specific effects from general mitotic stress responses, and evidence that immune remodeling improves patient outcomes.
Authors: Fazhi Yu, Shuaishuai Ji, Jing Guo, Zhenye Yang
Institution: University of Science and Technology of China
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7228437874
